Early Pulmonary Rehabilitation in Exacerbated COPD Patients
Launched by UNIVERSIDADE FEDERAL DE SAO CARLOS · Apr 24, 2017
Trial Information
Current as of June 16, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 40 years or more, of both genders, who are in a an exacerbation of the disease according to Global Initiative for Chronic Obstructive Lung Disease (GOLD,2015) refered by the doctors, hospitalized or not in exacerbation treatment .All patients should be in spontaneous breathing at the time of assessment, in oxygen use or not and in conditions to understand the proposed evaluations; Patients who use non-invasive ventilation will also be included as long as it does not interfere with the protocols; All should agree to participate in the research in a free and informed manner. Patients who are referred to the Intensive Care Unit (ICU) may be included 24 hours after discharge from the ICU.
- Exclusion Criteria:
- • Patients who present with orthopedic limitations, other pulmonary diseases, rheumatological, cardiovascular or neurological disorders that not allow the assessment. Patients whit drug os alcohol dependence, patients undergoing invasive mechanical ventilation, hemodynamic instability, the presence of unstable angina, will be excluded. In addition, patients with cognitive deficits that impair comprehension of the assessments will be excluded.
About Universidade Federal De Sao Carlos
The Universidade Federal de São Carlos (UFSCar) is a leading Brazilian institution dedicated to advancing research and education in the fields of science, technology, and health. With a strong emphasis on innovation and interdisciplinary collaboration, UFSCar fosters a vibrant academic environment that supports clinical trials aimed at addressing pressing health challenges. The university's commitment to high standards of ethical research and community engagement ensures that its clinical trials contribute valuable insights to the scientific community while promoting the well-being of diverse populations. Through its robust infrastructure and experienced research teams, UFSCar plays a pivotal role in advancing medical knowledge and improving patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sao Carlos, São Paulo, Brazil
Patients applied
Trial Officials
Valeria Di Lorenzo, PhD
Study Director
Universidade Federal de Sao Carlos
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials